{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:07:51Z","timestamp":1786709271865,"version":"build-2736575974"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jconrel.2024.06.044","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T20:29:38Z","timestamp":1719347378000},"page":"417-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Enhancing pulmonary delivery and immunomodulation of respiratory diseases through virus-mimicking nanoparticles"],"prefix":"10.1016","volume":"372","author":[{"given":"Yugo Ara\u00fajo","family":"Martins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel Cristina","family":"Guerra-Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara Silva","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Tapparel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata Fonseca Vianna","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.06.044_bb0005","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1038\/s41598-021-82852-7","article-title":"Morphometry of SARS-CoV and SARS-CoV-2 particles in ultrathin plastic sections of infected Vero cell cultures","volume":"11","author":"Laue","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0010","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3390\/ph14101059","article-title":"Physicochemical characteristics and in vitro toxicity\/anti-SARS-CoV-2 activity of favipiravir solid lipid nanoparticles (SLNs)","volume":"14","author":"Tulbah","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2024.06.044_bb0015","article-title":"Pulmonary delivery of remdesivir and dexamethasone encapsulated nanostructured lipid carriers for enhanced inflammatory suppression in lung","volume":"90","author":"Chen","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0020","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ajps.2021.09.002","article-title":"Liposomal remdesivir inhalation solution for targeted lung delivery as a novel therapeutic approach for COVID-19","volume":"16","author":"Li","year":"2021","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0025","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMra0910061","article-title":"Airway mucus function and dysfunction","volume":"363","author":"Fahy","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ni.3045","article-title":"Respiratory epithelial cells orchestrate pulmonary innate immunity","volume":"16","author":"Whitsett","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/B978-0-12-407697-6.00004-0","article-title":"Cellular and molecular biology of airway mucins","author":"Lillehoj","year":"2013","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0040","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.physiol.70.113006.100659","article-title":"Structure and function of the cell surface (tethered) mucins","volume":"70","author":"Hattrup","year":"2008","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0045","doi-asserted-by":"crossref","first-page":"22725","DOI":"10.1038\/s41598-021-02242-x","article-title":"MUC1 ectodomain is a flagellin-targeting decoy receptor and biomarker operative during Pseudomonas aeruginosa lung infection","volume":"11","author":"Verceles","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0050","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1038\/mi.2017.16","article-title":"The cell surface mucin MUC1 limits the severity of influenza A virus infection","volume":"10","author":"McAuley","year":"2017","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0055","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00281-016-0558-0","article-title":"The host immune response in respiratory virus infection: balancing virus clearance and immunopathology","volume":"38","author":"Newton","year":"2016","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0060","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02374-20","article-title":"Defensive properties of mucin glycoproteins during respiratory infections\u2014relevance for SARS-CoV-2","volume":"11","author":"Chatterjee","year":"2020","journal-title":"MBio"},{"key":"10.1016\/j.jconrel.2024.06.044_bb0065","first-page":"1","article-title":"Abnormal airway mucus secretion induced by virus infection","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0070","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41422-020-00435-z","article-title":"Mucus production stimulated by IFN-AhR signaling triggers hypoxia of COVID-19","volume":"30","author":"Liu","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0075","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/jmv.26406","article-title":"Elevated MUC1 and MUC5AC mucin protein levels in airway mucus of critical ill COVID-19 patients","volume":"93","author":"Lu","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0080","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.tim.2021.03.014","article-title":"Respiratory mucus as a virus-host range determinant","volume":"29","author":"Wallace","year":"2021","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0085","first-page":"1","article-title":"Sialic acid receptors of viruses","author":"Matrosovich","year":"2013","journal-title":"Top. Curr. Chem."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0090","article-title":"A beneficiary role for neuraminidase in influenza virus penetration through the respiratory mucus","volume":"9","author":"Yang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2024.06.044_bb0095","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.43764","article-title":"Influenza A virus surface proteins are organized to help penetrate host mucus","volume":"8","author":"Vahey","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.jconrel.2024.06.044_bb0100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.tim.2019.08.010","article-title":"Influenza A virus hemagglutinin\u2013neuraminidase\u2013receptor balance: preserving virus motility","volume":"28","author":"de Vries","year":"2020","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0105","doi-asserted-by":"crossref","first-page":"45043","DOI":"10.1038\/srep45043","article-title":"Influenza A virus hemagglutinin and neuraminidase act as novel motile machinery","volume":"7","author":"Sakai","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007233","article-title":"Kinetic analysis of the influenza A virus HA\/NA balance reveals contribution of NA to virus-receptor binding and NA-dependent rolling on receptor-containing surfaces","volume":"14","author":"Guo","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0115","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41594-019-0233-y","article-title":"Structural basis for human coronavirus attachment to sialic acid receptors","volume":"26","author":"Tortorici","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0120","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1166\/jbn.2015.2139","article-title":"Topical skin cancer therapy using doxorubicin-loaded cationic lipid nanoparticles and iontophoresis","volume":"11","author":"Huber","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10717544.2014.993486","article-title":"Development, optimization and evaluation of surfactant-based pulmonary nanolipid carrier system of paclitaxel for the management of drug resistance lung cancer using Box-Behnken design","volume":"23","author":"Kaur","year":"2014","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejps.2018.10.003","article-title":"Nanostructured lipid carriers versus solid lipid nanoparticles for the potential treatment of pulmonary hypertension via nebulization","volume":"125","author":"Nafee","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0135","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/jps.20644","article-title":"Analytical techniques for quantification of amorphous\/crystalline phases in pharmaceutical solids","volume":"95","author":"Shah","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0140","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ijpharm.2016.12.026","article-title":"Nebulized solid lipid nanoparticles for the potential treatment of pulmonary hypertension via targeted delivery of phosphodiesterase-5-inhibitor","volume":"517","author":"Makled","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0145","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ijpharm.2008.01.008","article-title":"Solid lipid nanoparticles for pulmonary delivery of insulin","volume":"356","author":"Liu","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2011.08.010","article-title":"Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers","volume":"157","author":"Ungaro","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.06.044_bb0155","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.carbpol.2016.10.076","article-title":"Hydrophilic polymeric nanoparticles prepared from Delonix galactomannan with low cytotoxicity for ocular drug delivery","volume":"157","author":"Ogunjimi","year":"2017","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ifset.2013.03.002","article-title":"Nanostructured lipid carriers (NLC): a potential delivery system for bioactive food molecules","volume":"19","author":"Tamjidi","year":"2013","journal-title":"Innov. Food Sci. Emerg. Technol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0165","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ejpb.2015.01.005","article-title":"Methods to determine the interactions of micro- and nanoparticles with mucus","volume":"96","author":"Grie\u00dfinger","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0170","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jconrel.2014.06.055","article-title":"Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors","volume":"192","author":"Nafee","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.06.044_bb0175","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/bit.23046","article-title":"Mannitol-guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model","volume":"108","author":"Yang","year":"2011","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0180","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.2147\/IJN.S113658","article-title":"Sulfonate-modified phenylboronic acid-rich nanoparticles as a novel mucoadhesive drug delivery system for vaginal administration of protein therapeutics: improved stability, mucin-dependent release and effective intravaginal placement","volume":"11","author":"Li","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.06.044_bb0185","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0003-2697(85)90442-7","article-title":"Measurement of protein using bicinchoninic acid","volume":"150","author":"Smith","year":"1985","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfa.2020.125070","article-title":"The influence of NLC composition on curcumin loading under a physicochemical perspective and in vitro evaluation","volume":"602","author":"Araujo","year":"2020","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0195","series-title":"European Pharmacopoeia","author":"Council of Europe","year":"2017"},{"key":"10.1016\/j.jconrel.2024.06.044_bb0200","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.2042-7158.1987.tb03142.x","article-title":"The twin impinger: a simple device for assessing the delivery of drugs from metered dose pressurized aerosol inhalers","volume":"39","author":"Hallworth","year":"1987","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0205","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3109\/10717544.2015.1055619","article-title":"Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect","volume":"23","author":"Wang","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0210","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1080\/10717544.2016.1217954","article-title":"Co-delivery of etoposide and curcumin by lipid nanoparticulate drug delivery system for the treatment of gastric tumors","volume":"23","author":"Jiang","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2019.110462","article-title":"Phthalocyanine-loaded nanostructured lipid carriers functionalized with folic acid for photodynamic therapy","volume":"108","author":"Oshiro-Junior","year":"2020","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.jconrel.2024.06.044_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109225","article-title":"Synergistic combination therapy of lung cancer: cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-demethylnobiletin","volume":"118","author":"Guo","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0225","series-title":"Int. Clin. Trials Regist. Platform","article-title":"A multicenter, adaptive, randomised, controlled trial platform to evaluated safety and efficacy of strategies and treatments for hospitalized patients with respiratory infections","author":"NIAID-NIH","year":"2022"},{"key":"10.1016\/j.jconrel.2024.06.044_bb0230","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jconrel.2010.02.006","article-title":"Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers","volume":"144","author":"Patlolla","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.06.044_bb0235","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.addr.2007.04.013","article-title":"Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering","volume":"59","author":"Bunjes","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0240","author":"FDA"},{"key":"10.1016\/j.jconrel.2024.06.044_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.03.017","article-title":"Formulation strategy and use of excipients in pulmonary drug delivery","volume":"392","author":"Pilcer","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0250","article-title":"Cellular uptake and retention of nanoparticles: insights on particle properties and interaction with cellular components","volume":"25","author":"Augustine","year":"2020","journal-title":"Mater. Today Commun."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0255","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejpb.2018.10.017","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: a review emphasizing on particle structure and drug release","volume":"133","author":"Gordillo-Galeano","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0260","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2019.10.035","article-title":"Rational particle design to overcome pulmonary barriers for obstructive lung diseases therapy","volume":"314","author":"He","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.06.044_bb0265","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1016\/j.biomaterials.2013.01.064","article-title":"Nanoparticle diffusion in respiratory mucus from humans without lung disease","volume":"34","author":"Schuster","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.06.044_bb0270","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1136\/thx.52.2008.S31","article-title":"The science of nebulised drug delivery","volume":"52","author":"Callaghan","year":"1997","journal-title":"Thorax"},{"key":"10.1016\/j.jconrel.2024.06.044_bb0275","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1164\/rccm.2312018","article-title":"Lysozyme in pulmonary host defense","volume":"169","author":"Skerrett","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0280","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0021-5198(19)52531-8","article-title":"A role of lysosomal enzymes in the mechanism of mucolytic action of bromhexine","volume":"33","author":"Takeda","year":"1983","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0285","doi-asserted-by":"crossref","first-page":"15698","DOI":"10.1074\/jbc.M313241200","article-title":"Identification of molecular intermediates in the assembly pathway of the MUC5AC mucin","volume":"279","author":"Sheehan","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0290","first-page":"L993","article-title":"Biosynthesis of the polymeric gel-forming mucin MUC5B","volume":"310","author":"Ridley","year":"2016","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0295","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejphar.2016.02.030","article-title":"Ambroxol inhalation ameliorates LPS-induced airway inflammation and mucus secretion through the extracellular signal-regulated kinase 1\/2 signaling pathway","volume":"775","author":"Zhang","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0300","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1465-9921-13-98","article-title":"Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells","volume":"13","author":"Seagrave","year":"2012","journal-title":"Respir. Res."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0305","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40248-017-0088-1","article-title":"A reappraisal of the mucoactive activity and clinical efficacy of bromhexine","volume":"12","author":"Zanasi","year":"2017","journal-title":"Multidiscip. Respir. Med."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0310","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/17425255.2019.1578748","article-title":"Enhancement of lung levels of antibiotics by ambroxol and bromhexine","volume":"15","author":"Deretic","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0315","doi-asserted-by":"crossref","first-page":"20547","DOI":"10.1074\/jbc.M110.121319","article-title":"Muc1 cell surface mucin attenuates epithelial inflammation in response to a common mucosal pathogen","volume":"285","author":"Guang","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0320","first-page":"1328","article-title":"Bacterial conjunctivitis in Muc1 null mice","volume":"40","author":"Kardon","year":"1999","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000617","article-title":"MUC1 limits Helicobacter pylori infection both by steric hindrance and by acting as a releasable decoy","volume":"5","author":"Lind\u00e9n","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0330","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1165\/rcmb.2011-0142OC","article-title":"Antiinflammatory role of MUC1 mucin during infection with nontypeable Haemophilus influenzae","volume":"46","author":"Kyo","year":"2012","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0335","first-page":"L558","article-title":"Antiinflammatory effect of MUC1 during respiratory syncytial virus infection of lung epithelial cells in vitro","volume":"298","author":"Li","year":"2010","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/347292","article-title":"Differential mucin expression by respiratory syncytial virus and human metapneumovirus infection in human epithelial cells","volume":"2015","author":"Ba\u00f1os-Lara","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0345","series-title":"The Glycosylated Extracellular Domain of MUC1 Protects against SARS-CoV-2 Infection at the Respiratory Surface","author":"Chatterjee","year":"2021"},{"key":"10.1016\/j.jconrel.2024.06.044_bb0350","doi-asserted-by":"crossref","first-page":"425","DOI":"10.5483\/BMBRep.2021.54.8.018","article-title":"MUC1-C influences cell survival in lung adenocarcinoma Calu-3 cells after SARS-CoV-2 infection","volume":"54","author":"Kim","year":"2021","journal-title":"BMB Rep."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01446","article-title":"The COVID-19 cytokine storm; what we know so far","volume":"11","author":"Ragab","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0360","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cytogfr.2020.06.001","article-title":"SARS-CoV-2 infection: the role of cytokines in COVID-19 disease","volume":"54","author":"Costela-Ruiz","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0365","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/imm.13223","article-title":"Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China","volume":"160","author":"Tan","year":"2020","journal-title":"Immunology"},{"key":"10.1016\/j.jconrel.2024.06.044_bb0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238160","article-title":"Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: a meta-analysis of 6320 patients","volume":"15","author":"Elshazli","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2024.06.044_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rmv.2141","article-title":"Interleukin-6 in Covid-19: a systematic review and meta-analysis","volume":"30","author":"Coomes","year":"2020","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0380","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2024.06.044_bb0385","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0390","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2172-8-8","article-title":"Interleukin-10 plays an early role in generating virus-specific T cell anergy","volume":"8","author":"Maris","year":"2007","journal-title":"BMC Immunol."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0395","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm1492","article-title":"Interleukin-10 determines viral clearance or persistence in vivo","volume":"12","author":"Brooks","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0400","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1084\/jem.20061462","article-title":"Resolution of a chronic viral infection after interleukin-10 receptor blockade","volume":"203","author":"Ejrnaes","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2024.06.044_bb0405","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.it.2020.10.012","article-title":"A potential role of interleukin 10 in COVID-19 pathogenesis","volume":"42","author":"Lu","year":"2021","journal-title":"Trends Immunol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924003936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924003936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T19:31:34Z","timestamp":1721935894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924003936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":81,"alternative-id":["S0168365924003936"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.06.044","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing pulmonary delivery and immunomodulation of respiratory diseases through virus-mimicking nanoparticles","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.06.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}